America's Blood Centers®
It's About Life.

ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2021 #10 **March 26, 2021**

INSIDE:

CBER Publishes Strategic Plan

The U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has published a strategic plan for 2021-25. According to a statement from CBER Director Peter Marks, MD, PhD, contained within the plan, the document "outlines the direction that we will take to support and achieve our mission and vision over the next five years." It also includes goals that are aligned with priorities at both the FDA and the U.S. Department of Health and Human Services (HHS). Stated goals within the plan include to:

- "[f]acilitate the development and availability of safe and effective medical products through the integration of advances in science and technology;
- [c]onduct research to address challenges in the development and regulatory evaluation of medical products;
- [i]ncrease preparedness for emerging threats and promote global public health; and
- [m]anage for strategic excellence and organizational accountability."

The agency also identifies its short-term priorities as:

- "[a]ddressing the COVID-19 outbreak;
- [d]eveloping a regulatory program for individualized or bespoke therapies;
- [f]acilitating compliance with human cells, tissues, and cellular and tissue-based product regulations; and
- [a]dvancing manufacturing technologies for biologic products."

The plan specifically states that "CBER will continue to leverage its Advisory Committees to access expert advice on challenges going forward, such as the continued evolution of blood safety policies through identification of additional information that could support alternative procedures to FDA's current time-based donor deferral policies and the use of pathogen reduction technologies.

Areas of interest within the plan that pertain to the blood community include the following strategies:

- "[d]evelop and facilitate application of innovative technologies toward universal pathogen reduction of the blood supply;" and
- "[c]ollaborate with the WHO, other regulators, manufacturers and NGOs to assure access to safe and effective vaccines, blood and blood products, and other medical products to address public health emergencies."

The complete strategic plan is available on the FDA website.

(Source: CBER Strategic Plan, 3/17/21)

REGULATORY NEWS

The Office of the Secretary at the U.S. Department of Health and Human Services (HHS) published a notice in the *Federal Register* this week on March 25th requesting a 60-day public comment period regarding a request from "[t]he Office of the Assistant Secretary for Health (OASH) [which] is [seeking] approval for a three-year revised information collection request (ICR) titled 'National Blood Collection & Utilization Survey (NBCUS).'" The notice states that "[t]he NBCUS is a biennial survey that includes a core of standard questions on blood collection, processing, and utilization practices. Questions on transfusion transmitted infections, transfusion associated circulatory overload, acute hemolysis, delayed hemolysis, and severe allergic reactions are also included in the survey. The rapidly changing environment in blood supply and demand makes it important to have regular, periodic data describing the state of U.S. blood collections and transfusions for understanding the dynamics of blood safety and availability. Two sections were added to the survey to capture information on the impact of the COVID-19 pandemic on the blood supply during the course of 2020 only. These data will be valuable, when compared to previous years, for understanding the effects of a major pandemic on the health system. Survey respondents will consist of blood collection centers, cord blood banks and hospitals that perform blood transfusions, except those reporting fewer than 100 inpatient surgeries per year. For the purposes of this ICR, federal burden is only being placed on facilities located within the fifty states and the District of Columbia." Individuals can submit comments by email by May 24th with the document identifier 0990-0313-60D.

(Source: *Federal Register* Announcement, 3/25/21)

The U.S. Food and Drug Administration (FDA) published a notice in the *Federal Register* on March 26th requesting nominations for voting members to serve on the Blood Products Advisory Committee (BPAC) in the Center for Biologics Evaluation and Research (CBER). Nominations for vacancies must be received by May 25th. The agency requests that all nominations for membership should be sent electronically by logging into the FDA Advisory Nomination Portal. More information about becoming a member on an FDA advisory committee can also be obtained by visiting FDA's website. The BPAC Committee "reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology that are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which FDA has regulatory responsibility. The Committee also advises the [FDA Commissioner] of its findings regarding screening and testing (to determine eligibility) of donors and labeling of the products, on clinical and laboratory studies involving such products, on the affirmation or revocation of biological products licenses, and on the quality and relevance of FDA's research program that provides the scientific support for regulating these agents."

(Source: *Federal Register* Announcement, 3/26/21)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail.

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers
Chief Executive Officer: Kate Fry
Chief Medical Officer: Rita Reik
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: $390

Send subscription queries to
memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.

COVID-19 Convalescent Plasma Updates



Upcoming ABC Webinars – Don't Miss Out!

- **ABC SMT Journal Club Webinar** – March 31st from 1 – 2 p.m. (ET). Additional details including login information to join the webinar are available to ABC members in MCN 21-028. Please contact us with questions or to receive a copy of the MCN.

- **ADRP Convalescent Plasma Donors — "What's Next? Webinar** – April 21st from 1 – 2 p.m. (ET). Additional details and registration available here.

America's Blood Centers®
It's About *Life.*

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

Register for ADRP Master Class: Elevate Your Donor Journey

Registration is now open for the next ADRP Master Class scheduled to take place on May 12th-13th. Blood centers are encouraged to have their collections and recruitment teams participate in the virtual event that will delve into the topic of improving donor experience. The master class will begin by mapping the donor journey, then focus on donor programs, and conclude with ways to improve staff selection, training, and culture. ADRP is excited to have speakers from blood centers of all sizes and external industries including Chick-fil-A, Customer Experience Professional Association (CXPA), Ritz Carlton, and more. This event is designed for recruitment and collections professionals as both disciplines are important in the donor journey. View the complete program and register today here.

March SMT Journal Club Webinar

The America's Blood Centers (ABC) Scientific, Medical, and Technical (SMT) Journal Club Webinar on March 31st at 1 p.m. EDT will feature the articles below:

- The effect of red blood cell transfusion on fatigability after hospital discharge (*Blood Advances*);
- Fecal blood loss: A quantitative method of evaluating hemostasis in patients with thrombocytopenia (*Transfusion*); and
- HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men (*Transfusion*).

Additional details including login information to join the webinar are now available to ABC members in MCN 21-028. Please contact us with questions or to receive a copy of the MCN.

(Source: MCN 21-028, 3/17/21)

ABC Member Value Report Now Available

ABC has published the fiscal year 2021 (April 1st, 2020 – March 31st, 2021) member value report. It provides a snapshot of the work completed over the previous year on behalf of member blood centers. ABC encourages member blood center to review the report and actively engage with us by providing feedback. Also, please share the report with members of your staff and board of directors to communicate the continued value of your ABC membership. Thank you for all you did to contribute to an outstanding year.

(Source: ABC Member Value Report, 3/15/21)

PEOPLE

George Eastwood has been named chief commercial officer at San Diego Blood Bank. According to an announcement from the blood bank, he has spent his career in sales and commercial operations while working at several life science companies including Harvard Apparatus, ThermoFisher Scientific, and Hamilton and Lonza. Mr. Eastwood was also one of the first employees to join HemaCare (now a division of Charles River Labs) as the organization transitioned to a supplier of raw materials in the cell and gene therapy space. He has also worked at BIOIVT where Mr. Eastwood led their strategy within the immunology and cell therapy space, which included the acquisition of three donor center-based businesses. He received his Bachelor of Science degree in Toxicology at Northeastern University. In his new role at San Diego Blood Bank, Mr. Eastwood will focus on growing the blood bank's research products and services and cell therapies businesses.

(Source: San Diego Blood Bank Announcement, 3/25/21)

WORD IN WASHINGTON

Vice Admiral Vivek Murthy, MD, MBA has been confirmed by the U.S. Senate as the 21st Surgeon General. He previously held the role under former President Barack Obama from 2014 to 2017. According to his bio on the U.S. Department of Health and Human Services (HHS) website, Dr. Murthy "has created initiatives to tackle our country's most pressing public health challenges. As "America's Doctor he helped lead the national response to a range of health challenges, including the Ebola and Zika viruses, the opioid crisis, and the growing threat of stress and loneliness to Americans' physical and mental wellbeing. He also issued the first Surgeons General's report on Alcohol, Drugs and Health, in which he challenged the nation to expand access to prevention and treatment and to recognize addiction as a chronic illness, not a character flaw…His scientific research has focused on vaccine development and the participation of women and minorities in clinical trials. And as an internal medicine doctor at Brigham and Women's Hospital and at Harvard Medical School, Dr. Murthy cared for thousands of patients over the years and trained undergraduates, medical students, and medical residents. He his Bachelor of Arts degree from Harvard, his MBA from the Yale School of Management, and his MD from the Yale School of Medicine."

(Source: HHS Announcement, 3/25/21)

The U.S. Senate also confirmed Rachel Levine, MD as the 17th Assistant Secretary for Health (ASH) at HHS. Her bio states "Dr. Rachel Levine fights every day to improve the health and well-being of all Americans. She [is] working to help our nation overcome the COVID-19 pandemic and build a stronger foundation for a healthier future - one in which every American can attain their full health potential. After graduating from Harvard College and Tulane University School of Medicine, Dr. Levine completed her training in Pediatrics and Adolescent Medicine at the Mt. Sinai Medical Center in New York City. As a physician, she focused on the intersection between mental and physical health, often treating children, adolescents, and young adults. Dr. Levine was a Professor of Pediatrics and Psychiatry at the Penn State College of Medicine…In 2015, Pennsylvania Governor Tom Wolf nominated Dr. Levine to be Pennsylvania's Physician General and she was subsequently unanimously confirmed by Pennsylvania's state Senate. In 2017, Dr. Levine was named Acting

(continued on page 6)

WORD IN WASHINGTON (continued from page 5)

Secretary of Health and confirmed to the position in March of 2018. During her time in state government, Dr. Levine worked to address Pennsylvania's opioid crisis, focus attention on maternal health and improve immunization rates among children. Dr. Levine is a Fellow of the American Academy of Pediatrics, the Society for Adolescent Health and Medicine, and the Academy for Eating Disorders. She was also the President of the Association of State and Territorial Health Officials."

(HHS Announcement, 3/26/21)

President Biden recently announced his "intent to nominate" Dawn O'Connell to serve as Assistant Secretary for Preparedness and Response (ASPR) at HHS. According to a news release from the administration, Ms. O'Connell "is currently the Senior Counselor to the Secretary for COVID-19. In this role, she coordinates the [d]epartment-wide response to the pandemic. Prior to assuming this role, [she] served on the[n] [President-elect] Biden['s] Transition Team as the health cluster lead for the Nominations Team. She was also the Director of the Coalition for Epidemic Preparedness and Innovation's (CEPI) U.S. Office…[Ms. O'Connell] also served as the executive director for CEPI's Joint Coordination Group—a roundtable of institutional partners who all have a vested interest in the successful development and deployment of epidemic vaccines. Prior to joining CEPI in June 2017, she was a Senior Counselor to Secretary Sylvia Burwell at [HHS] during the Obama Administration. As Senior Counselor, Ms. O'Connell advised Secretary Burwell on high-priority global health and humanitarian issues, including infectious diseases, unaccompanied children, and refugees. She worked with HHS leaders, the White House, and other federal and international partners, to resolve key policy challenges, lead implementation, and drive progress toward Administration goals. She received her undergraduate degree in literature from Vanderbilt University and her law degree from Tulane University School of Law."

(White House News Release, 3/19/21)

MEMBER NEWS

The Oklahoma Senate recently passed legislation that would provide a tax incentive to businesses that host blood drives for their employees, according to a report from KFOR-TV. Oklahoma State Senator David Bullard filed the bill, which he worked with **Oklahoma Blood Institute** on. Senate Bill 905 "would provide an income tax credit for tax years 2022 through 2027 to businesses that host blood drives for their employees...an income tax credit of $20 per employee donor to businesses that host onsite blood drives. The total statewide cap for the credit is set at $500,000 and will sunset after tax year 2027." The bill now heads to the Oklahoma House of Representatives for consideration (as of March 9th) according to KFOR-TV. "Between the pandemic and the historic winter storm last month, our state blood supplies are dangerously low. Oklahoma is no stranger to natural disasters, but it's important that our blood reserves stay full year-round regardless of what's happening in the state," said Sen. Bullard to KFOR-TV. "I worked with the Oklahoma Blood Institute on this bill, and we think by providing a tax incentive, more businesses would be willing to host blood drives and get their employees involved in helping their fellow Oklahomans and saving lives… Blood is a special need that unlike other essentials, like food or clothing, can't be manufactured or produced when demand increases. It has to come from the gracious donations of our fellow Oklahomans," Bullard said. "Our state's hospitals and health care industry require approximately 1,200 daily blood donations just to meet the basic health needs of our state. This will create a private/public partnership to help ensure our state always has the lifesaving blood supply our citizens need."

(Source: KFOR-TV, Bill that provides tax incentive for business blood drives passes Oklahoma Senate, 3/9/21)

(continued on page 7)

MEMBER NEWS (continued from page 6)

South Texas Blood and Tissue Center recently honored three 100+ gallon donors at a recognition event. One of the donors, Marcos Perez made national and international news for his achievement including being interviewed on segment for the national television morning show "Live with Kelly and Ryan." Mr. Perez was born prematurely and received a transfusion during his infancy. That inspired him to become a donor on a regular basis as he continues to donate platelets every two weeks. He hopes others follow his lead as he stated in a news release from South Texas Blood and Tissue Center, "[i]f people in this town can back the [San Antonio] Spurs (the city's professional basketball franchise), they can back the blood bank, too," said Mr. Perez. "They need to pay it forward – one donation saved my life, and that means thousands of people are alive today [because of blood donations]."

(Sources: South Texas Blood and Tissue Center News Release, 3/19/21; Live with Kelly and Ryan, 3/22/21)

GLOBAL NEWS

The World Health Organization (WHO) issued a statement on behalf of its Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee regarding the safety of AstraZeneca's COVID-19 vaccine. The statement contains recommendations and conclusions from the subcommittee based on a review on clinical trial data and safety data from Europe, the United Kingdom, India, and the WHO's global safety reports database (VigiBase). The recommendations include:

- "the AstraZeneca COVID-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world.
- The available data do not suggest any overall increase in clotting conditions such as deep venous thrombosis or pulmonary embolism following administration of COVID-19 vaccines. Reported rates of thromboembolic events after COVID-19 vaccines are in line with the expected number of diagnoses of these conditions. Both conditions occur naturally and are not uncommon. They also occur as a result of COVID-19. The observed rates have been fewer than expected for such events.
- While very rare and unique thromboembolic events in combination with thrombocytopenia, such as cerebral venous sinus thrombosis (CVST), have also been reported following vaccination with the AstraZeneca COVID-19 vaccine in Europe, it is not certain that they have been caused by vaccination. The European Medicines Agency's Pharmacovigilance and Risk Assessment Committee has reviewed 18 cases of CVST out of a total of more than 20 million vaccinations with the AstraZeneca COVID-19 vaccine in Europe. A causal relationship between these rare events has not been established at this time.
- Adequate education should be provided to health-care professionals and persons being vaccinated to recognize the signs and symptoms of all serious adverse events after vaccinations with all COVID-19 vaccines, so that people may seek and receive prompt and relevant medical care and treatment.
- The GACVS subcommittee recommends that countries continue to monitor the safety of all COVID-19 vaccines and promote reporting of suspected adverse events.
- The GACVS subcommittee also agrees with the European Medicines Agency's plans to further investigate and monitor for these events."

(Source: WHO Statement, 3/19/21)

NHS Blood and Transplant (NHSBT), the national blood provider for England and transplant services for the United Kingdom (UK) received a £4.6 million in funding to form a gene therapy hub. The gene therapy grant aims to develop new treatment options for individuals with rare of life-threatening

(continued on page 8)

GLOBAL NEWS (continued from page 7)

diseases. "Gene therapies have huge potential and this funding will enable NHS Blood and Transplant to be at the heart of developing these new medical advances," said NHSBT Chief Medical Officer and Director of Clinical Services Gail Miflin in a NHSBT news release. "This grant will allow the NHS to better collaborate on novel gene therapies, which we hope will mean new treatment options for patients with rare illnesses who are least likely to benefit from existing options. We are confident the new hub will help strengthen the UK's position as an international leader in gene therapy research and innovation." NHSBT also announced in the news release that the gene therapy hub will be located at its Bristol site and be "one of a network of three cutting-edge gene therapy innovation hubs funded by an £18 million grant by LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC)… Due to be operational by the end of 2021, the new facility will support early phase academic-led gene therapy trials and facilitate the provision of cost-effective viral vectors and plasmid DNA to stimulate the UK's gene therapy sector. The hub, led by Dr Jon Smythe and Dr Paul Lloyd-Evans, will provide viral vector manufacturing, training and support services for academic-led groups seeking Adeno Associated Viral (AAV), Lentiviral (LV) vectors and plasmid DNA at GMP and research-grade qualities."

(Source: NHSBT News Release, 3/18/21)

The WHO recently certified El Salvador as "malaria-free)" making it the first country in Central America to be designated as such. "Malaria has afflicted humankind for millennia, but countries like El Salvador are living proof and inspiration for all countries that we can dare to dream of a malaria-free future," said WHO Director-General Tedros Adhanom Ghebreyesus, PhD in a statement from the organization. El Salvador is third country to be designated malaria-free in recent years in the WHO Region of the Americas, joining Argentina and Paraguay. According to the WHO statement, the organization grants the certification to countries who have "proven, beyond reasonable doubt, that the chain of indigenous transmission has been interrupted nationwide for at least the previous three consecutive years. With the exception of one outbreak in 1996, El Salvador steadily reduced its malaria burden over the last three decades. Between 1990 and 2010, the number of malaria cases declined from more than 9000 to 26. The country has reported zero indigenous cases of the disease since 2017."

(Source: WHO Statement, 2/25/21) ♦

COMPANY NEWS

AstraZeneca announced positive results from the primary analysis of a U.S. phase III trial of its COVID-19 vaccine candididate. In the news release, the company stated the results have been provided to the Independent Data Safety Monitoring Board and "will be the basis for a regulatory submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration in the coming weeks." The analysis revealed, "the accrual of 190 symptomatic cases of COVID-19 from the 32,449 trial participants, an additional 49 cases to the previously announced interim analysis. Participants were randomised on a 2:1 ratio between the vaccine and placebo group. The primary endpoint, vaccine efficacy at preventing symptomatic COVID-19 was 76% (confidence interval (CI): 68 percent to 82 percent) occurring 15 days or more after receiving two doses given four weeks apart. In addition, results were comparable across age groups, with vaccine efficacy of 85 percent (CI: 58 percent to 95 percent) in adults 65 years and older. A key secondary endpoint, preventing severe or critical disease and hospitalisation, demonstrated 100 percent efficacy. There were eight cases of severe COVID-19 observed in the primary analysis with all of those cases in the placebo group. The vaccine was well tolerated, and no safety concerns related to the vaccine were identified."

(Source: AstraZeneca News Release, 3/25/21)

(continued on page 9)

COMPANY NEWS (continued from page 8)

Ortho Clinical Diagnostics has created a resource hub of COVID-19 convalescent plasma (CCP) tools to help educate clinicians and aid lab professionals. The tools include white papers, scientific insights, webinars, podcasts, and more. A new scientific evidence book is also available on the hub that highlights peer-reviewed articles regarding CCP safety and efficacy. Clinicaians can also find learning cards to demonstrate the fundamentals of CCP. They are broken down into seven key areas: overview; mechanisms of action, collection and testing; uses and clinical outcomes; programs for access and donor eligibility; guidelines and protocols; serology testing; and other treatments for COVID-19. Audio learnings and additional updates and resources are available of Ortho's podcast channel.

(Source: Ortho Clinical Diagnostics CCP Resource Hub, 3/24/21)

Regeneron Pharmaceuticals, Inc. announced "positive topline results" for a phase III trial of its monclonal antibody therapy in non-hospitalized COVID-19 patients. According to a company news release, the "phase III outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the investigational REGEN-COV™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death by 70 percent (1,200 mg intravenous [IV]) and 71 percent (2,400 mg IV) compared to placebo." Regeneron added in the release that, "REGEN-COV also met all secondary endpoints in the Phase III outcomes trial, including the ability to reduce symptom duration. In addition, a companion Phase II trial showed that even the lowest doses tested (IV: 300 mg; subcutaneous [SC]: 600 mg) had significant viral load reductions over the first seven study days, comparable to the 2,400 mg and 1,200 mg IV doses." The company stated that it will request "the 1,200 mg dose be rapidly added to the [EUA], in order for the anticipated REGEN-COV supply to be available to treat even more patients."

(Source: Regeneron Pharmaceuticals, Inc. News Release, 3/23/21) ♦

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The calendar of events includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the

Cellphire Request for Apheresis Platelet Units

Cellphire, Inc. is a biomedical research organization located in Rockville, M.D. Currently, Cellphire is conducting two separate Phase II clinical trials. Both trials require a weekly supply of FDA licensed, leukocyte reduced, Apheresis Platelet Units (APU). For one trial, IND 17156, the APUs, once received by Cellphire, are pooled, filtered using a process of Tangential Flow Filtration (TFF) which reduces the excess plasma, then a cryoprotectant solution is added to the pooled APU, aliquoted to glass vials, and then lyophilized. The lyophilized product is termed "Thrombosomes". For the other trial, IND 14047, the APU have an added requirement. They must be licensed, irradiated and leukocyte reduced. These APUs are plasma reduced, mixed with 6% percent DMSO, and then frozen and stored in an Ultra-Low Freezer at ≤-65C. These DMSO frozen platelets are termed "CPP". Information on each of these clinical trials may be found on Clinicaltrials.gov. More information available here.

CALENDAR

Note to subscribers: *Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

2021

April 15. **FDA Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (Virtual).** More details available here.

May 4-6. **IPFA/PEI 27th International Workshop on Surveillance and Screening of Blood-borne Pathogens (Virtual).** More details available here.

May 12-13. **Elevate Your Donor Journey: ADRP Master Class in Finding Your XFactor (Virtual).** More details available here.

May 21-22. **64th Annual California Blood Bank Society Annual Meeting (Virtual).** More details available here.

Aug. 4. **ABC Medical Directors Workshop, Cleveland, Ohio.** More details coming soon.

Aug. 5-6. **ABC Summer Summit, Cleveland, Ohio.** More details coming soon.

Aug. 17-19. **2021 ADRP Conference, Kansas City, Mo.** More details coming soon.

Sept. 15-17. **4th European Conference on Donor Health and Management, Hamburg, Germany.** More details available here.

Oct. 16-19. **AABB Annual Meeting.** More details available here.

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: $139 per placement for *ABC Newsletter* subscribers and $279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Chief Clinical Officer. The Central California Blood Center seeks ideal candidates for a new position of Chief Clinical Officer (CCO). Looking for a blood banking/transfusion medicine leader who can successfully navigate the ever-changing health care provider and blood industry landscapes to provide ever increasing value to our clients. The CCO will provide clinical, scientific, and technical expertise, supporting our senior management team, for our innovative and independent community blood center. The CCO will oversee blood component manufacturing, donor testing lab, R&D programs, IRL, donor services and IT departments. The position will be responsible for developing strategies to ensure blood manufacturing operations are running efficiently and growing effectively to meet the needs of our hospitals and clients, with a focus on excellence and compliance. The CCO will shape and guide our team of high-achieving department leaders to consistently exceed standards and goals for cGMP, productivity, and customer service. MS, SBB, PhD or MD preferred. Strong and progressive blood industry leadership experience required. Includes opportunities for further career advancement. Please send inquiries to lchristiansen@donateblood.org.

Vice President, Donor Sourcing (Collections) (Anywhere, USA). Vitalant is a nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the United States. Under minimal direction, this position is responsible for Donor Sourcing policies and procedures ensuring effective and efficient processes for the Blood Services Division. Requirements: Bachelor's degree required. Master's preferred. Knowledge of large system operations management including fiscal policies, human resource management, and strategic planning required. Knowledge of federal, state, and local regulations that affect business operations required. Ten years of related experience required. To include: Six years senior leadership experience. Prior executive experience and knowledge of collections process preferred. Apply here. EOE

Operations Coordinator of Mobile Staging. OUR WORK IS LIFE-SAVING…YOURS CAN BE TOO! Join our team as an Operations Coordinator of Mobile Staging! You will be responsible for overseeing all aspects of Bedford/Waco Mobile Staging and Centralized Scheduling. This includes development and implementation of all operational activities with emphasis on continuous process and improvement. Responsible for overseeing the preparation of payroll, supplies, equipment, vans, coaches, and finalization of mobile drive schedules needed for daily mobile operations. Responsible for overall management of mobile staging and

scheduling technicians. If you have at least three years of Management experience and want to be a part of making a difference please apply here on our company website to be considered. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

Donor Recruitment Manager (Blood Assurance, Nashville area). Supervise and lead our Account Managers field recruitment efforts that build new and existing business in the assigned communities served by Blood Assurance. Assist in developing long-term community business partnerships, and coordinating internally with all leadership levels to support or expand Blood Assurance recruitment efforts. Qualified candidates will have a bachelor's degree in business, marketing, or related field. Advanced communication skills, organizational skills, teamwork, customer service, follow up, networking, negotiation, and judgment. Also requires initiative, creative problem solving, conflict resolution, staff management and development. The hiring process begins with submitting an online employment application at www.bloodassurance.org. Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

Operations Manager (Blood Assurance, Nashville area). Manage our collection efforts in the greater Nashville, TN and surrounding areas. This position will be responsible for operational oversight of collection services for multiple collection teams in an assigned territory. Supervises staff in coordination with other department leaders and ensures compliance with all Standard Operating Procedures, FDA and AABB regulations. Monitors performance in the areas of productivity, proficiency, and customer service. Bachelor's degree required with some prior supervisory/management experience in blood banking is required. The hiring process with submitting an online employment application at www.bloodassurance.org. Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

(continued on page 12)

POSITIONS (continued from page 11)

Medical Technologist or MLT (Blood Assurance, Nashville area). Position in our Nashville lab location to perform basic to complex serologic patient testing and interpret result to determine donor-recipient compatibility. May consult and communicate with staff at other medical facilities, to resolve serologic problems and provide special units to transfusion recipients. Qualified candidates must have current State of Tennessee Medical Laboratory license and AS/BS Degree. Strong blood banking skills preferred. The hiring process begins with submitting an online employment application at www.bloodassurance.org. Blood Assurance is an EOE and Tobacco-Free work environment. All employment offers will be contingent upon successful completion of a positive background and employment references review and a negative drug test result.

Specialist in Blood Banking (SBB) Certificate Program. The LifeSouth Specialist in Blood Banking (SBB) certificate program, an independent educational program offering training in all aspects of blood banking and transfusion medicine, is accepting applications for the 2021-2022 class. Starting date is 06/14/2021. Application deadline has been extended to 04/30/2021. Click here for additional information.

Assistant Manager of Component Production (Carter BloodCare). Functions: The Assistant Manager of Component Production will assist the Manager in all aspects of coordination of Component Production manufacturing functions. You will oversee daily operations, direct supervision of the production team, interviews, adhere to the fiscal budget, and any task to ensure efficient workflow with strong judgment and decisiveness. You will also collaborate with other blood centers on projects and corporate initiatives. Education: MLT ASCP or equivalent. Experience: Two years' supervisory experience in blood banking production, OR five years' supervisory experience in a government-regulated production environment, OR combination of education and experience. Two years' experience with computer blood banking/inventory management software. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities (EEO) to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing. Click here to apply.

Medical Affairs Counselor (Scottsdale, AZ). Vitalant is a nonprofit organization that collects blood from volunteer donors and provides blood, blood products and services across the United States. Under minimal supervision, this position is responsible for verbally counseling donors, physicians, and customers on the medical significance of infectious disease markers and responding to questions and concerns. Bachelor's degree or equivalent combination of education and experience required. Extensive working knowledge of infectious diseases preferred. RN license or Certification as a Medical Technologist by a recognized certifying agency preferred. Three years' experience in a healthcare environment required. To include: Experience in patient and/or donor education/counseling/communication. Please apply here. EOE

Phlebotomist/Collections Instructor. Carter BloodCare is hiring an Instructor to our team in Bedford, Texas. The Instructor position is responsible for the training and continuing education of the Collection Services staff in all procedures involved in the allogeneic and special donation collection process. This includes but is not limited to medical history, donor lookup, phlebotomy, quality control, CPR, basic apheresis, and a minimum of one apheresis technology. This position is also responsible for ensuring that trainees receive adequate clinical experience, safely performing all required skills and successfully completing competency testing. They plan for and guide the learning process to help students achieve objectives required within the allotted time. They must have adequate transportation to travel. Please click here to apply. Carter BloodCare is an EEO/Affirmative Action employer. Carter BloodCare provides equal employment opportunities to all employees and applicants and will not discriminate in its employment practices due to an employee's or applicant's race, color, religion, sex, sexual orientation, gender identity, age, national origin, genetic, and veteran or disability status. In addition to federal law requirements, Carter BloodCare complies with applicable state and local laws governing nondiscrimination in employment in every location in which the company has facilities. Carter BloodCare is a Pro Disabled & Veteran Employer. We maintain a drug-free workplace and perform pre-employment substance abuse testing.

OneBlood has exciting career opportunities available in the incredible state of Florida! Join our life saving mission in one of the following roles: **Reference Lab Manager (Ft. Lauderdale, FL).** Valid and current Florida Clinical Laboratory Supervisor license in Immunohematology or Blood Banking and SBB certification required. Bachelor's degree in medical technology or related field with five (5) or more years' experience; prior management experience essential. **Compatibility Testing Lab Supervisor (Tallahassee, FL - $5k Bonus**

(continued on page 13)

POSITIONS (continued from page 12)

Eligible). Bachelor's degree in medical technology, biological science, or related field and three plus years in a clinical laboratory, preferably in blood banking. Requires a current Florida Technologist license in Immunohematology or Blood Banking; FL Supervisor License preferred. **Medical Technologist (Tallahassee, FL - $5k Bonus Eligible).** A valid and current Florida Clinical Laboratory Technologist license in Immunohematology or Blood Banking is required. Prior blood banking experience preferred. Multiple shifts available. **Therapeutics Apheresis RN (Ft. Lauderdale, FL - $5k Bonus Eligible).** Current and valid Florida RN license, current BLS CPR certification, and a valid and clear driver's license is required. Flexibility in scheduling needed to meet the needs of the department; travel within the tri-county market in the South Florida area is required. OneBlood offers competitive benefits, including excellent shift differential pay for night and weekend schedules, Paid Time Off, Student Loan Repayment Program, a FREE medical coverage option, 403(b) Retirement Plan, company-paid annual CEU training & CE Broker account and MORE! To apply visit our OneBlood careers website at www.oneblood.org/careers.